Navigation Links
Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results
Date:8/22/2007

SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today that results from a series of HIV vaccine Phase 2a clinical trials, using a plasmid DNA (pDNA) vaccine developed by the NIH Vaccine Research Center and manufactured by Vical, reinforced previously reported Phase 1 conclusions that a "DNA prime-adenoviral vector boost" vaccine regimen was safe and well-tolerated, and was effective in inducing T-cell immune responses in up to 70% of the vaccine recipients.

"These recent vaccine trials contribute to the growing body of knowledge demonstrating plasmid DNA priming as a key factor in achieving significant immune responses against HIV, a particularly difficult target pathogen, bringing us one step closer to evaluating the effectiveness of a prime-boost HIV vaccine regimen in a prophylactic setting," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The latest International AIDS Vaccine Initiative (IAVI) listing of ongoing preventive HIV vaccine clinical trials shows that more than half use pDNA either alone or in combination with other vaccine modalities. We are very pleased that DNA technology is an integral part of the effort to address this high priority global health problem."

The trials involved priming an immune response with three doses of a pDNA vaccine over a two month period, based on Vical's proprietary DNA technology, and boosting the response with a single dose of adenoviral vector vaccine at six months. The three trials, collectively known as TRIAD, were conducted by the National Institute of Allergy and Infectious Diseases (NIAID) HIV Trials Vaccine Network (HVTN), the IAVI, and the U.S. Military HIV Research Program (USMHRP). Richard Koup, M.D., Chief of Immunology at the Dale and Betty Bumpers Vaccine Research Center (VRC), NIAID, National Institutes of Health (NIH), highlighted TRIAD summary results and conclusions in an oral presentation, "Update on safety and immunogenicity
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Concord Medical Services ... CCM ), a leading specialty hospital management ... of radiotherapy and diagnostic imaging centers in ... of a purchase agreement under which Concord Medical ... of the Company, agreed to acquire the Fortis ...
(Date:3/26/2015)... 2015  The Burzynski Research Institute, Inc. (BRI) announced ... by the Department of Surgery at Kurume University ... have been published. The study, a randomized non-blinded ... as post-operative adjuvant therapy with and without Antineoplastons ... A total of 65 patients, ...
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... Schein, Inc. (Nasdaq: HSIC ), the largest provider ... today that it will release its third quarter 2010 financial ... 2010, and will provide a live webcast of its earnings ... Eastern Daylight Time. Speakers on the call will include Stanley ...
... PITTSBURGH, Oct. 15 Mylan Inc. (Nasdaq: ... Inc. received final approvals from the U.S. Food and ... (ANDAs) for the generic versions of Hyzaar® Tablets, 50 ... 25 mg, 50 mg and 100 mg, both antihypertensives. ...
Cached Medicine Technology:Henry Schein to Webcast Third Quarter 2010 Conference Call Friday, October 29, at 10:00 a.m. EDT 2Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar® 2
(Date:3/27/2015)... PRUSSIA, PA and LONDON, UK (PRWEB) March 27, 2015 ... President of DrugDev SiteStart Melissa (Liss) Easy was named ... , The 40 Under 40 list spotlights 40 ... for their professional accomplishments and community involvement. Winners are ... in a special supplement of the Philadelphia Business Journal. ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement ... on and analysis of the healthcare, regulatory and reimbursement ... in 2013 amounted to 316.1 million, having grown at ... 2008. The country’s increasingly elderly population and corresponding increase ... boost the growth of the pharmaceutical market, which was ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global MEMS pressure ... MEMS based ultra-miniature pressure sensor designed especially for the ... 220um x 75um provides ample space for 1-French catheter ... industry leading in vivo drift performance of 2 ... pressure range from 0 to 1,100 mmHg absolute. ...
(Date:3/27/2015)... 2015 When struck with the aftermath ... know where to begin. The latest eBook released ... attorney, offers accident victims a clear and concise process ... ensure their personal injury claim is seen through to ... first actions that should be taken immediately following the ...
(Date:3/27/2015)... To address their number one lawn care question which ... this video to explain the complicated dynamics between the light ... expected to thrive in, be it in dense building or ... Anytime a sun-loving plant is put in the shade the ... try to amend this issue by applying large quantities of ...
Breaking Medicine News(10 mins):Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:For Spring Turf Planting Season, Super-Sod Created a New How-To Video Entitled "Two Views on Shade and Turf" 2
... earlier Rhode Island Hospital study looking at data from ... per year were seen in emergency departments across the ... which examined emergency department visits from 2000 through 2005, ... the study period, an average of 88,563 each year. ...
... Shopping on the Internet may not be as environmentally friendly, ... and Traders are anything to go by. ... home deliveries has outweighed the reduction in carbon dioxide emissions ... said. ,The total CO2 emitted by cars fell ...
... the University of Southern California have identified a chemical ... brain to low blood sugar levels . ... to yield new insights in the fight against diabetes, ... the researchers, the chemical travels from the hindbrain, which ...
... in Massachusetts, resulting in calls mosquito spraying, though environmentalists ... a potentially deadly encephalitis. Though the incidence is rising, ... of objections from environmentalists. ,Nine regional control ... the time, the Norfolk County Mosquito Control Project, which ...
... found that grandchildren, who were taken care of by their ... of their grandparents as they age . ,The ... their grandparents and received their care and concern, were more ... ,"Even little things, like occasional babysitting for a ...
... made significant advances towards the development of a technique that ... variant CJD . ,The technique, which has so ... and accelerating the replication of prions - abnormal proteins that ... the disease. ,The method, known as known as ...
Cached Medicine News:Health News:Higher Rates of Trampoline Injuries 2Health News:Neurotransmitter That can Yield New Insights in the Fight Against Diabetes Identified 2Health News:Eastern Equine Encephalitis Spreading Its Tentacles in Massachusetts 2Health News:Eastern Equine Encephalitis Spreading Its Tentacles in Massachusetts 3Health News:Grandparents' Care Makes Grandchildren More Caring for Them 2Health News:Significant Advances in VCJD Prion Detection 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: